GLAND logo

Gland Pharma Limited Stock Price

NSEI:GLAND Community·₹321.5b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 11 Fair Values set on narratives written by author

GLAND Share Price Performance

₹1,951.40
242.30 (14.18%)
16.6% undervalued intrinsic discount
₹2,340.00
Fair Value
₹1,951.40
242.30 (14.18%)
13.5% undervalued intrinsic discount
₹2,256.67
Fair Value
Price ₹1,951.40
AnalystHighTarget ₹2,256.67
AnalystConsensusTarget ₹1,862.83
AnalystLowTarget ₹1,138.00

GLAND Community Narratives

AnalystHighTarget·Updated
Fair Value ₹2.34k 16.6% undervalued intrinsic discount

Global Aging And Healthcare Infrastructure Expansion Will Spur High-Value Injectables

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·Updated
Fair Value ₹1.86k 4.8% overvalued intrinsic discount

Expanded Manufacturing Capacity Will Unleash Market Opportunity

0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AnalystLowTarget·Updated
Fair Value ₹1.22k 60.0% overvalued intrinsic discount

Rapid GLP-1 Capacity Increase Will Erode Profit Margins

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative

Recent GLAND News & Updates

Gland Pharma Limited's (NSE:GLAND) P/E Is On The Mark

Sep 15
Gland Pharma Limited's (NSE:GLAND) P/E Is On The Mark

Here's What Analysts Are Forecasting For Gland Pharma Limited (NSE:GLAND) After Its First-Quarter Results

Aug 08
Here's What Analysts Are Forecasting For Gland Pharma Limited (NSE:GLAND) After Its First-Quarter Results

Gland Pharma's (NSE:GLAND) Dividend Is Being Reduced To ₹18.00

Aug 05
Gland Pharma's (NSE:GLAND) Dividend Is Being Reduced To ₹18.00

Is Gland Pharma (NSE:GLAND) Using Too Much Debt?

Jul 17
Is Gland Pharma (NSE:GLAND) Using Too Much Debt?

Gland Pharma Limited Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next

May 23
Gland Pharma Limited Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next

Gland Pharma Limited Key Details

₹57.2b

Revenue

₹24.2b

Cost of Revenue

₹33.0b

Gross Profit

₹25.3b

Other Expenses

₹7.7b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 29, 2025
Earnings per share (EPS)
46.75
Gross Margin
57.73%
Net Profit Margin
13.46%
Debt/Equity Ratio
3.4%

Gland Pharma Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Excellent balance sheet with reasonable growth potential.

0 Risks
1 Reward

About GLAND

Founded
1978
Employees
4351
CEO
Shyamakant Giri
WebsiteView website
www.glandpharma.com

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro-intestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain/analgesics, respiratory and pulmonology, and vitamins, minerals, and nutrients. In addition, it provides contract development, dossier compilation, technology transfer services. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

Indian Market Performance

  • 7 Days: 1.5%
  • 3 Months: -1.7%
  • 1 Year: -4.7%
  • Year to Date: 0.7%
Over the last 7 days, the market has risen 1.5%, driven by gains of 2.3% in the Financials sector. In contrast, the market has seen a decline of 4.7% over the last 12 months. Earnings are forecast to grow by 16% annually. Market details ›